You are here: Industry Insights > J&J

News List

J&J snaps up Idorsia’s resistant hypertension candidate, paying $230M fiercebiotech
December 05, 2017
Swiss biotech Idorsia spun out of Actelion before it was taken over by Johnson & Johnson earlier this year, but the big pharma has confirmed it will still play a big part in one of its lead products.
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits fiercepharma
November 23, 2017
Last year, real-world data showed that SGLT2 diabetes drugs could significantly cut heart failure hospitalizations and all-cause deaths.
J&J abandons Remicade patent fight against Samsung and its Renflexis biosim fiercepharma
November 15, 2017
Pharma giant Johnson & Johnson is determined to defend Remicade against a growing biosimilar attack, but now the company has dropped its lawsuit accusing Samsung Bioepis of infringing patents on the blockbuster immunology drug.
FDA advisers reject J&J rheumatoid arthritis drug pharmaphorum
August 04, 2017
The chances of Johnson & Johnson’s rheumatoid arthritis drug sirukumab getting approved in the US look slim, after the FDA’s expert advisers raised concerns about its safety.
J&J’s type 2 diabetes drug INVOKANA significantly reduces major heart complications in CANVAS progra biospectrumasia
June 28, 2017
These data from the integrated analysis of the CANVAS and CANVAS-R trials were published in the New England Journal of Medicine, and presented in a special symposium at the American Diabetes Association 77th Scientific Sessions.
J&J completes acquisition of Actelion cphi-online
June 23, 2017
Actelion will now become part of the Janssen Pharmaceutical Companies of J&J.
Financial Report: Johnson & Johnson contractpharma
April 20, 2017
Domestic sales increased 0.6%. International sales increased 2.8%, reflecting operational growth of 3.6% and a negative currency impact of 0.8%.
J&J acquires Neuravi to bolster neuro business pharmafile
April 12, 2017
Johnson & Johnson’s neurosurgery and neurovascular unit, Codman Neuro, has made the move to acquire ...
J&J chief Gorsky, in China for official summit, straddles Trump's globalism divide fiercepharma
March 23, 2017
Amid uncertainty for pharma as President Donald Trump embarks on his quest of putting “America First,” Johnson & Johnson CEO Alex Gorsky played down the potential fallout for his company during a CNBC interview Monday.
J&J to shutter West Lothian plant pharmatimes
March 13, 2017
Healthcare giant Johnson & Johnson is planning to close its medical manufacturing plant in West Lothian, Scotland, potentially affecting around 400 jobs.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page